{"id":831878,"date":"2025-03-31T17:16:25","date_gmt":"2025-03-31T21:16:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/"},"modified":"2025-03-31T17:16:25","modified_gmt":"2025-03-31T21:16:25","slug":"compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/","title":{"rendered":"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET.<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>BOSTON, March  31, 2025  (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2\/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).\u00a0<\/p>\n<p>\n        <strong>Webinar Details:<\/strong>\n      <\/p>\n<p>Date: Tuesday, April 1, 2025<\/p>\n<p>Time: 8 AM EDT<\/p>\n<p>Webcast: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=72Gw0BbesnMdl6mLKt30MrCHkvbP2iUG7lpp9C6Gxgg2J8wYtP9kUrhwQMiYjtEXCY7-OqWzkzUZJzTSO5gSJj3fuQ0KO93P1ibocE97HxZ78iOP3C8ovWNgWSX6e1k9Jj5dazJSDR6a_TXXYQSUS_Tm9b8jyJaNg8Dxxrkh84YBVxAylcedWfUx5k9deUNEQ3ZHQ8b6BvMVEyHP0VgKEBLMqxIenSAKnadoIyM8sznynbQYv1UVPx9rvgWfN3Hjc1xVw7XqvloYtBTDKynIyttbOZBNm9w8eTxI-12CMEbVRYONYy4EGj96evOszs6nUbvxBg5jZuqCn-PBx6Ms0xMK5SH5ZpKbWfehJWeb3wOI9MatEuq6_le0vmLo_OKnDKcnuVnxlQ3DiVXIqkZMTEIQcP2v038NLuh2DC-VwD1a1ETn38mXmzU23OTMt4BDQPtuMFvS-D-uLgAKYoaGNXSFCALH9o6iDye8KeFggHczzBNT4NeFq3gaq7SV_7iArioim2AGC71JMBrLOxD88AoaOO4eCqWH7Iamf9WxFz8Zq9HYRQFiU96fk-mqavnuGBuWqrg8m54ymQtfsKoARO5LwN3UIMgvg8GVc_k3QRpWqe8NtSQLh8pyDeG53BJ75fuSakwm9rQLL6vw4c6kC2XC5jddLK1s5nKTrDVMXnswd0ZwqPnSl9gT0_wzPYc_Bg_K4vzbQcH5vxe1zkV0D7XpccrZli8pX17llynbT8Jgns6_40ayGNxANaxMFhuCebDxJ-H9jn11t_7rWt-61A==\" rel=\"nofollow\" target=\"_blank\">https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1712286&amp;tp_key=3b05c5ebcd<\/a><\/p>\n<p>Virtual\/Replay availability: A replay will be archived for 90 days on Compass\u2019 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vaQhoWXJPZKZqOYPy5_0AS3awjOFgLDDSzkA64Dxl7WRCflSdXFNtpTTQWDBMHAq-oF_vpdqzTm0GsDZ_HWf4MKfCuYedfG8_wTBjyiYPffRjsQ9atEAd2nXZGXCzauA\" rel=\"nofollow\" target=\"_blank\">Events<\/a> page.<\/p>\n<p>\n        <strong>About Compass Therapeutics<\/strong><br \/>\n        <br \/>Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=72Gw0BbesnMdl6mLKt30Mtr_HDKKht80aYbeHXshpUGerbmG_U61Tbs95hsTgYZun36tZUOnUISlelyDcApwptjnxQ4Cpq_LfhJkRKCCW6n-mydsr4BQnN-X-lxcvPeKRm8BXast06Lx40vCG-BgPiJDoh6Pm6n8lhG9MqYoour74G8hu_PIskFVxRw9gVjW2zMtxfb1GbwfeK1rBjfOH1MyIpwtSaRDjkqrYxWemiiSJAPHrCWRl4EiOis56G2iOk16LtVCz55SSq9fWdFQD9Ar7o32QUdbM8EZ7aHudJIoSWyljtI2BnZ4n4ncd5InwgW-6IkRVxpN8c9oSSuTJuvy_ZGEzwWaYUDJlLZBJGSAjiIESn6ZLj4X7jwDvqi51jgTDo58ohSV1K1g8Ylci-wcm-2GTcqXJwt5Q58tuTwOnTBzkQKBKWWCSKUsBxUmJjXcsfmjALJ4fHRwukoRQvmOcnUT1mp9ZtiVc7_ez6DuOsIpudVnDpFxefL2w9H6OkeRO63bOv9FecsRLnekVR2Np9XtFhKuQa_VdSsbwe6Mvk_rl84ahjxkH7Z4fAHij8m4cpfzAFhaazZmpIb3ERwnyjWnet8TtoydjPZjiRljou9LSH6Pe21PaMsrXsVv_ZaQ5dnWPqOr-Sii58_K8cGMz7GdOtyxbHz0ePsU4h8A7iuzQtARM5Y0ED5bWjIm\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.compasstherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gUsusmn6OL2IdLX1Qf3iFnt03y69cxgKdqKN00FYaeCxk_UikKdI00zyWMp5YVK5i3TLFz60iQrF5CInrMuImeP2Mxx7Xn8gdbCX8RJr1JwRu2pF2j_AG5gcVntLQbN0\" rel=\"nofollow\" target=\"_blank\">ir@compasstherapeutics.com<\/a>\n      <\/p>\n<p>\n        <strong>Media Contact <\/strong><br \/>\n        <br \/>Anna Gifford, Chief of Staff <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kiSFiAe0P_XcWUTNwTqQd3c3iKkluwsRX28Hloe8yKwrNEeJSseH1VFKacOooeVLneh03MO0sD-G3ly60iYtuKz5SvgX7WikNsz6FgbJKM8l1VikBs8qdmWWxeAr0EhR\" rel=\"nofollow\" target=\"_blank\">media@compasstherapeutics.com<\/a><br \/>617-500-8099<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDYxYTM1MTctZTRmMi00M2Q4LTk3OTYtNjkwZDQwZTE1YTAzLTEyMTM5NzUtMjAyNS0wMy0zMS1lbg==\/tiny\/Compass-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2\/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).\u00a0 Webinar Details: Date: Tuesday, April 1, 2025 Time: 8 AM EDT Webcast: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1712286&amp;tp_key=3b05c5ebcd Virtual\/Replay availability: A replay will be archived for 90 days on Compass\u2019 Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-831878","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2\/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).\u00a0 Webinar Details: Date: Tuesday, April 1, 2025 Time: 8 AM EDT Webcast: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1712286&amp;tp_key=3b05c5ebcd Virtual\/Replay availability: A replay will be archived for 90 days on Compass\u2019 Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a &hellip; Continue reading &quot;Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-31T21:16:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\\\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer\",\"datePublished\":\"2025-03-31T21:16:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/\"},\"wordCount\":298,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/\",\"name\":\"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\\\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=\",\"datePublished\":\"2025-03-31T21:16:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\\\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk","og_description":"Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2\/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).\u00a0 Webinar Details: Date: Tuesday, April 1, 2025 Time: 8 AM EDT Webcast: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1712286&amp;tp_key=3b05c5ebcd Virtual\/Replay availability: A replay will be archived for 90 days on Compass\u2019 Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a &hellip; Continue reading \"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-31T21:16:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer","datePublished":"2025-03-31T21:16:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/"},"wordCount":298,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/","name":"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=","datePublished":"2025-03-31T21:16:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI1NiM2ODQzNzkyIzIyMDI0MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing-randomized-phase-2-3-study-evaluating-tovecimig-in-patients-with-biliary-tract-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2\/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=831878"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831878\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=831878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=831878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=831878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}